1. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. (December 2022) Authors: Papadopoulos, K.; Li, T.; Lakhani, N.; Powderly, J.; George, T.; Teoh, D.G.K.; Kilari, D.; Giaccone, G.; Sanborn, R.E.; Ghamande, S.; LoRusso, P.; Gibney, G.; Ma, V.T-L.; Yalamanchili, K.; Brown, J.; Mota, N.; Tasillo Kadra, C.; Umiker, B.; Xiao, X.; Trehu, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 188P IPH5201 as monotherapy or in combination with durvalumab (D) in advanced solid tumours. (December 2022) Authors: Imbimbo, M.; Hollebecque, A.; Italiano, A.; McKean, M.; Macarulla, T.; Castanon Alvarez, E.; Carneiro, B.A.; Mager, R.; Barnhart, V.; Murtomaki, E.; He, Y.; Cooper, Z.A.; Tu, E.; Linke, A.; Fan, C.; Zhou, D.; Boyer Chammard, A.; Paturel, C.L.; Fraenkel, P.G.; Powderly, J. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors. (December 2022) Authors: Csiki, I.; Glenn, J.; Boccia, R.; Chen, C.; Gordon, M.; Misleh, J.; Powderly, J.; Wainberg, Z.A.; Spira, A.; Klumpp, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3110 Safety and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced, unresectable mesothelioma: A phase IB trial. (September 2015) Authors: Hassan, R.; Thomas, A.; Patel, M.; Nemunaitis, J.; Bennouna, J.; Powderly, J.; Taylor, M.; Cuillerot, J.M.; Heydebreck, A. Von; Gulley, J.L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. (September 2015) Authors: Giaccone, G.; Camidge, D.R.; Liu, S.V.; Powderly, J.; Hodi, F.S.; Gettinger, S.N.; Heist, R.S.; Liu, B.; Wallin, J.; Funke, R.; Waterkamp, D.; Ready, N.E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗